TECHNOVAX INC has a total of 22 patent applications. Its first patent ever was published in 2007. It filed its patents most often in United States, WIPO (World Intellectual Property Organization) and Canada. Its main competitors in its focus markets pharmaceuticals, biotechnology and environmental technology are MEDIGEN INC, PALESE PETER and IMMUNICUM AB.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 8 | |
#2 | WIPO (World Intellectual Property Organization) | 7 | |
#3 | Canada | 2 | |
#4 | China | 2 | |
#5 | EPO (European Patent Office) | 2 | |
#6 | Japan | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Environmental technology |
# | Technology | |
---|---|---|
#1 | Microorganisms | |
#2 | Therapeutic chemical compounds | |
#3 | Medical preparations | |
#4 | Peptides | |
#5 | Climate change adaptation technologies | |
#6 | Fermentation |
# | Name | Total Patents |
---|---|---|
#1 | Galarza Jose M | 16 |
#2 | Martin George R | 8 |
#3 | Boigard Helene | 7 |
#4 | Galarza Jose | 5 |
#5 | Cimica Velasco | 5 |
#6 | Matassov Demetrius | 4 |
#7 | Martin George | 3 |
#8 | Wen Ke | 1 |
#9 | Jose Galarza | 1 |
#10 | Fulvini Andrew A | 1 |
Publication | Filing date | Title |
---|---|---|
WO2020219703A1 | Recombinant circovirus capsid-virus-like particle (vlp): compositions, methods and uses | |
US2019030156A1 | Human respiratory syncytial virus (hrsv) virus-like particles (vlps) based vaccine | |
WO2016210127A1 | Flavivirus and alphavirus virus-like particles (vlps) | |
CN102858368A | Universal virus-like particle (vlp) influenza vaccines | |
WO2011046925A1 | Respiratory syncytial virus (rsv) virus-like particles (vlps) | |
WO2007130330A2 | Polyvalent influenza virus-like particle (vlp) compositions | |
WO2007130327A2 | Influenza virus-like particle (vlp) compositions |